英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Adjudging查看　Adjudging　在百度字典中的解释百度英翻中〔查看〕
Adjudging查看　Adjudging　在Google字典中的解释Google英翻中〔查看〕
Adjudging查看　Adjudging　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
  • Update 2025: Management of Non‑Small-Cell Lung Cancer - PMC
    Abstract Lung cancer remains the leading cause of cancer-related mortality worldwide Since 2024, the non–small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering in an era of personalized treatment with improved
  • FDA Approves Alectinib for ALK-Positive Lung Cancer
    Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
  • Non-Small Cell Lung Cancer - Guidelines Detail - NCCN
    Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7 2025
  • FDA approves alectinib as adjuvant treatment for ALK-positive . . .
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK . . .
    Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study Here, we report long-term outcomes from CROWN after 5 years of follow-up
  • Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . .
    INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [1,2] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
  • Advanced ALK-Positive NSCLC: Treatment Sequencing Insights . . .
    In the field of lung cancer, multiple studies focused on treatment strategies for patients with advanced ALK-positive NSCLC, with the potential to further advance evolving treatment paradigms in
  • FDA Grants Fast Track Designation to TRI-611 in ALK-Positive . . .
    The U S Food and Drug Administration has granted Fast Track designation to TRI-611 for the treatment of ALK-positive non-small cell lung cancer, marking an important regulatory step for one of the more unusual drug candidates now entering the lung cancer space TRI-611 is not a conventional ALK tyrosine kinase inhibitor It is an oral, brain-penetrant molecular glue degrader designed to
  • Alectinib in combination with bevacizumab as first . . . - Nature
    Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy This work reports a phase 2 trial





中文字典-英文字典  2005-2009